The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers

What's known on the subject? and What does the study add? A growing body of evidence supports the anti‐cancer effect of histone deacetylase inhibitors (HDACi) in vitro, via multiple pathways, and many Phase I clinical trials have shown them to be well‐tolerated in a range of malignancies. Combi...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BJU international Ročník 111; číslo 4; s. 537 - 542
Hlavní autori:	Sharma, Naomi L., Groselj, Blaz, Hamdy, Freddie C., Kiltie, Anne E.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Oxford Wiley-Blackwell 01.04.2013
Predmet:	Animals Antineoplastic Agents - therapeutic use Biological and medical sciences cancer Clinical Trials as Topic Combined Modality Therapy combined therapy Disease Models, Animal HDAC inhibitor Histone Deacetylase Inhibitors - therapeutic use Histone Deacetylases - drug effects Histone Deacetylases - genetics Humans In Vitro Techniques Male Medical sciences Molecular Targeted Therapy - methods Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nephrology. Urinary tract diseases Prognosis Prospective Studies Radiotherapy, Adjuvant Risk Assessment Survival Rate Treatment Outcome Tumors Urologic Neoplasms - drug therapy Urologic Neoplasms - genetics Urologic Neoplasms - mortality Urologic Neoplasms - pathology urology combined therapy Histone deacetylase Histone deacetylase inhibitor Nephrology Urinary system HDAC inhibitor Combined treatment Malignant tumor Urinary tract Urology Cancer
ISSN:	1464-4096, 1464-410X, 1464-410X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!